Patient recruitment for clinical trials is a significant bottleneck, necessitating a balance between scientific rigor and practical considerations.
2
The complexity of clinical trials has increased, making patient recruitment more challenging due to evolving regulatory requirements and specific inclusion criteria.
3
Boards and executives must adapt to the intensified competition in drug development, as outdated strategies hinder funding opportunities.
4
Accurate measurement of target engagement in tissues is crucial, as current reliance on plasma-based assays limits the ability to address underlying challenges.
5
Translational predictability remains a major bottleneck, especially for neurodegenerative diseases, due to reliance on inadequate model systems.
